Inventiva announces participation at several investor conferences in October 2021
28 September 2021 - 10:00PM
Inventiva announces participation at several investor conferences
in October 2021
Daix (France), Long Island City (New
York, United States), September
28, 2021 – Inventiva (Euronext Paris and Nasdaq: IVA), a
clinical-stage biopharmaceutical company focused on the development
of oral small molecule therapies for the treatment of non-alcoholic
steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other
diseases with significant unmet medical need, today announced that
the Company’s leadership will participate in three upcoming
investor conferences in October 2021.
The event details are as follows:
Conference
n°1:
HealthTech Innovation Days 2021Event type:
One-on-one investor
meetingsDate:
Monday-Tuesday, October 4-5,
2021Time:
3:00 am – 12:00 pm (ET) / 9:00 am – 6:00 pm
(CET)Format:
Hybrid event
Conference
n°2:
Portzamparc Health Biotech SeminarEvent type:
One-on-one investor
meetingsDate:
Wednesday, October 6,
2021Time:
3:00 am – 12:15 pm (ET) / 9:00 am – 6:15 pm
(CET)Format:
Hybrid event
Conference
n°3:
H.C. Wainwright 5th Annual NASH Investor ConferenceEvent
type:
Corporate presentation, one-on-one investor
meetingsDate:
Monday, October 11,
2021Time:
2:00 am – 12:00 pm (ET) / 8:00 am – 6:00 pm
(CET)Format:
Virtual event
About Inventiva
Inventiva is a clinical-stage biopharmaceutical
company focused on the development of oral small molecule therapies
for the treatment of NASH, MPS and other diseases with significant
unmet medical need.
Leveraging its expertise and experience in the
domain of compounds targeting nuclear receptors, transcription
factors and epigenetic modulation, Inventiva is currently advancing
two clinical candidates, as well as a deep pipeline of preclinical
programs.
Lanifibranor, its lead product candidate, is
being developed for the treatment of patients with NASH, a common
and progressive chronic liver disease for which there are currently
no approved therapies. In 2020, Inventiva announced positive
topline data from its Phase IIb clinical trial evaluating
lanifibranor for the treatment of patients with NASH and obtained
both FDA Breakthrough Therapy and Fast Track designation for
lanifibranor in the treatment of NASH. Lanifibranor is currently
being evaluated in a pivotal Phase III clinical trial.
Inventiva is also developing odiparcil, a second
clinical stage asset, for the treatment of patients with subtypes
of MPS, a group of rare genetic disorders. Inventiva announced
positive topline data from its Phase IIa clinical trial evaluating
odiparcil for the treatment of adult MPS VI patients in 2019 and
received both FDA Fast Track and Rare Paediatric Disease
designation for odiparcil in MPS VI.
In parallel, Inventiva is in the process of
selecting an oncology development candidate for its Hippo
signalling pathway program. Furthermore, the Company has
established a strategic collaboration with AbbVie in the area of
autoimmune diseases. AbbVie has started the clinical development of
ABBV‑157, a drug candidate for the treatment of moderate to severe
psoriasis resulting from its collaboration with Inventiva. This
collaboration enables Inventiva to receive milestone payments upon
the achievement of pre-clinical, clinical, regulatory and
commercial milestones, in addition to royalties on any approved
products resulting from the collaboration.
The Company has a scientific team of
approximately 70 people with deep expertise in the fields of
biology, medicinal and computational chemistry, pharmacokinetics
and pharmacology, as well as in clinical development. It also owns
an extensive library of approximately 240,000 pharmacologically
relevant molecules, approximately 60% of which are proprietary, as
well as a wholly‑owned research and development facility.
Inventiva is a public company listed on
compartment C of the regulated market of Euronext Paris (ticker:
IVA - ISIN: FR0013233012) and on the Nasdaq Global Market in the
United States (ticker: IVA). www.inventivapharma.com.
Contacts
Inventiva Pascaline ClercVP Global External
Affairsmedia@inventivapharma.com+1 240 620 9175 |
Brunswick GroupYannick Tetzlaff /Tristan Roquet
Montegon /Aude LepreuxRelations médiasinventiva@brunswickgroup.com
+33 1 53 96 83 83 |
Westwicke, an ICR CompanyPatricia L. BankRelations
investisseurspatti.bank@westwicke.com +1 415 513-1284 |
- Inventiva - PR - October events - 27 09 2021
Inventiva (EU:IVA)
Historical Stock Chart
Von Feb 2024 bis Mär 2024
Inventiva (EU:IVA)
Historical Stock Chart
Von Mär 2023 bis Mär 2024